Please login to the form below

Not currently logged in
Email:
Password:

Michael Wyzga OncoMed board

He brings financial experience from Genzyme

Michael Wyzga OncoMedOncoMed has appointed industry veteran Michael Wyzga to the company's board of directors.

The cancer specialist is looking to make the most of Wyzga's years in the industry as it prepares to advance the development of its five drug candidates, with several new filings planned for 2014.

This experience includes serving as chief financial officer of the biotech Genzyme from 1998 to 2011, when the company was acquired by Sanofi in what was the second-largest acquisition in biotech history.

He is currently president and CEO of biopharma company Radius Health having joined the company in December 2011.

"As a CEO of an emerging biopharmaceuticals company and previous chief financial officer of one of the leading biotechnology companies in the world, Mike brings an excellent perspective to OncoMed's board following our successful initial public offering," said Paul Hastings, chairman and CEO of OncoMed.

In addition to its own prospects, OncoMed also has development deals with major pharma companies, including GlaxoSmithKline and Bayer.

23rd October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics